Holen Sie sich die Stockscreener-App
129.31
1.18%
-1.55
Handel nachbörslich:
129.96
0.65
+0.50%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt GILD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$130.86
Offen:
$130.93
24-Stunden-Volumen:
5.43M
Relative Volume:
0.75
Marktkapitalisierung:
$160.55B
Einnahmen:
$29.79B
Nettoeinkommen (Verlust:
$9.22B
KGV:
17.59
EPS:
7.3494
Netto-Cashflow:
$10.23B
1W Leistung:
-3.70%
1M Leistung:
+3.32%
6M Leistung:
-4.87%
1J Leistung:
+14.23%
1-Tages-Spanne:
$129.04
$131.65
1-Wochen-Bereich:
$127.61
$135.50
52-Wochen-Spanne:
$108.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Firmenname
Gilead Sciences Inc
Sektor
Telefon
(650) 574-3000
Adresse
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
129.31 | 162.47B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,196.03 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 624.12B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 453.92B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 322.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.01 | 296.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | Jefferies | Buy |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-02-11 | Bestätigt | Needham | Buy |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-08-19 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | Hochstufung | Truist | Hold → Buy |
| 2025-07-25 | Hochstufung | Needham | Hold → Buy |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2025-02-18 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Hochstufung | DZ Bank | Hold → Buy |
| 2025-01-10 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-11-08 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-10-21 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-07 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Bestätigt | Maxim Group | Buy |
| 2024-04-24 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Herabstufung | Truist | Buy → Hold |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-09-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-16 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-01-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Fortgesetzt | BofA Securities | Neutral |
| 2022-12-09 | Herabstufung | DZ Bank | Buy → Hold |
| 2022-10-31 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Bestätigt | BMO Capital Markets | Market Perform |
| 2022-10-28 | Bestätigt | Cowen | Outperform |
| 2022-10-28 | Bestätigt | JP Morgan | Overweight |
| 2022-10-28 | Bestätigt | Jefferies | Buy |
| 2022-10-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-10-28 | Hochstufung | Truist | Hold → Buy |
| 2022-10-28 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-10-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-28 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-02 | Bestätigt | BofA Securities | Neutral |
| 2022-02-02 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-02-02 | Bestätigt | Truist | Hold |
| 2022-02-02 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Argus | Hold → Buy |
| 2022-01-06 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Neutral |
| 2021-11-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Fortgesetzt | Piper Sandler | Neutral |
| 2021-10-20 | Fortgesetzt | Cowen | Outperform |
| 2021-07-30 | Bestätigt | BMO Capital Markets | Market Perform |
| 2021-07-30 | Bestätigt | RBC Capital Mkts | Outperform |
| 2021-04-01 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Hochstufung | Redburn | Neutral → Buy |
| 2021-01-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-09-30 | Fortgesetzt | Jefferies | Buy |
| 2020-09-15 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-07-31 | Bestätigt | Credit Suisse | Neutral |
| 2020-07-31 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Bestätigt | Piper Sandler | Overweight |
| 2020-07-31 | Bestätigt | RBC Capital Mkts | Outperform |
| 2020-07-31 | Bestätigt | SunTrust | Hold |
| 2020-07-31 | Bestätigt | Wells Fargo | Equal Weight |
| 2020-07-20 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Hochstufung | SunTrust | Sell → Hold |
| 2020-05-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Herabstufung | SunTrust | Hold → Sell |
| 2020-04-27 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Herabstufung | CFRA | Hold → Sell |
Alle ansehen
Gilead Sciences Inc Aktie (GILD) Neueste Nachrichten
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance Singapore
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
J&J, Gilead among recipients of EU drug recommendations this week - Seeking Alpha
Gilead Sciences Inc (NASDAQ:GILD): A Quality Dividend Stock for Income Investors - ChartMill
Why Investors Are Watching Bristol Myers Squibb, Gilead Sciences and Amgen - Kalkine Media
Gilead’s Trodelvy gets EU panel backing for breast cancer combo By Investing.com - Investing.com Canada
in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer - Business Wire
EU panel recommends Trodelvy-Keytruda after 35% lower progression-or-death risk - Stock Titan
GILD|Gilead Sciences Inc|Price:130.840|Chg%:+0.500 - TradingKey
Gilead Sciences stock trades steady as HIV and oncology pipeline supports long term growth - AD HOC NEWS
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? - The Motley Fool
Can Gilead's Efforts to Develop New Treatments Solidify HIV Franchise? - Yahoo Finance
ETFs Investing in Gilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S Stocks - TradingView
How Gilead Is Working With Cultural Influencers to Bring Attention to HIV Stigma and Elevate HIV Prevention - IMDb
Gilead, Merck weekly HIV pill maintains suppression in Phase III switch studies - The Pharma Letter
Why Is Gilead Sciences (NASDAQ:GILD) Trending on the Nasdaq? - Kalkine Media
[AIDS 2026] [Press release] Gilead & Meck: Investigational once-weekly oral HIV treatment regimen of islatravir and lenacapavir maintained virological suppression in adults with HIV who switched antiretroviral therapy - European AIDS Treatment Group
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026 - Yahoo! Finance Canada
Gilead Sciences to release Q2 2026 results on August 4 - scanx.trade
Gilead, Merck weekly HIV pill keeps virus suppressed in late-stage trials - Reuters
ETFs Investing in Gilead Sciences, Inc. Stocks - TradingView
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Press Release: Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Moomoo
Gilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026 - Business Wire
Gilead and Merck report weekly HIV trial results - grafa.com
GILD Downgraded by Leerink Partners -- Price Target Lowered to $127 - GuruFocus
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pill - Benzinga
Preferred dividends of Gilead Sciences, Inc. – BCS:GILDCL1 - TradingView
Gilead to present HIV prevention and treatment data at AIDS 2026 - Investing.com Canada
Gilead, Merck’s phase 3 data back first weekly HIV pill - Fierce Pharma
Press Release: Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Moomoo
Gilead Sciences' Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Adobe, Datadog, Five Below, Fortinet, Gilead Sciences, Goldman Sachs, Microsoft, Salesforce, and More - 24/7 Wall St.
Analyst recommendations: Gilead, Salesforce, Goldman Sachs, Carvana, Crowdstrike… - marketscreener.com
Gilead Sciences stock trades steady as HIV and oncology pipeline supports outlook - Ad-hoc-news.de
Lobbying Update: $1,590,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today - Benzinga
Gilead Sciences (GILD) Downgraded by Leerink Partners Amid Marke - GuruFocus
Car T Cell Therapy Market Set to Booming Growth 2026-2033 | Novartis AG, Gilead Sciences, Inc - EIN News
Gilead Sciences stock trades steady as HIV and oncology pipeline underpins recent earnings - Ad-hoc-news.de
Gilead Sciences stock trades steady as HIV and oncology portfolio supports earnings trajectory - ad-hoc-news.de
Assembly Biosciences: A Gilead-Backed Antiviral Option With More Embedded Leverage Than The Market Appreciates - Seeking Alpha
Gilead Sciences (GILD) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Gilead Built Its Foundation On HIV; Is It Now In Trouble? - Investor's Business Daily
With Up To Date campaign, Gilead brings HIV prevention into the dating conversation - Medical Marketing and Media
Gilead Sciences synthesizes new KRAS mutant inhibitors - BioWorld News
Gilead Sciences chief comm & corp aff officer sells $389,757 in stock By Investing.com - Investing.com South Africa
Gilead Sciences stock trades steadily as oncology progress and HIV franchise support valuation - ad-hoc-news.de
Form 4 Gilead Sciences Inc For: 16 July By Investing.com - Investing.com Nigeria
Gilead Sciences CFO Andrew Dickinson sells $389,776 in stock By Investing.com - Investing.com South Africa
Insider Sell: Johanna Mercier Sells Shares of Gilead Sciences In - GuruFocus
Finanzdaten der Gilead Sciences Inc-Aktie (GILD)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.88%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):